On September 5th, the U.S. FDA granted full approval for our medicine to slow kidney function decline in adults with IgA nephropathy. For more information, see our Press Release.
Search for information about a product, therapeutic area or event
Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
Sparsentan, the dual endothelin angiotensin receptor antagonist(DEARA), attenuates albuminuria and protects from thedevelopment of renal injury to a greater extent than losartan inthe gddY mouse model of IgA nephropathy; a 16-week study
Sparsentan Protects the GlomerularBasement Membrane and Glycocalyx, andAttenuates Proteinuria in a Rat Model ofFocal Segmental Glomerulosclerosis (FSGS)
Baseline Characteristics of PatientsEnrolled in the Ongoing Phase 3Randomized, Double-Blind, Active-Control Trial of Sparsentan for theTreatment of Focal SegmentalGlomerulosclerosis (DUPLEX)
Baseline Characteristics of PatientsEnrolled in the Ongoing Phase 3Randomized, Double-Blind, Active-Control Trial of Sparsentan for theTreatment of Immunoglobulin ANephropathy (PROTECT)
The Dual Endothelin Angiotensin Receptor Antagonist (DEARA) Sparsentan Protects From Glomerular Hypercellularity and Associated Immune/Inflammatory Gene-Network- Activity in a Model of IgA Nephropathy
The Dual Endothelin Angiotensin Receptor Antagonist (DEARA) Sparsentan Protects From Glomerular Hypercellularity and Associated Immune/Inflammatory Gene-Network- Activity in a Model of IgA Nephropathy
Sparsentan, the dual endothelin and angiotensin receptor antagonist (DEARA), improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes